PMID- 27828731
OWN - NLM
STAT- MEDLINE
DCOM- 20170302
LR  - 20170302
IS  - 1751-2441 (Electronic)
IS  - 1751-2433 (Linking)
VI  - 10
IP  - 2
DP  - 2017 Feb
TI  - The pharmacological challenges of treating tuberculosis and HIV coinfections.
PG  - 213-223
LID - 10.1080/17512433.2017.1259066 [doi]
AB  - Tuberculosis (TB) is the most prevalent opportunistic infection among HIV 
      patients, and the leading cause of death among HIV patients worldwide. 
      Simultaneous treatment of both diseases is recommended by current guidelines, but 
      can be challenging due to the potential for drug-drug interactions, overlapping 
      toxicities, difficulty adhering to medications, and an increased risk for immune 
      reconstitution inflammatory syndrome (IRIS). Clinical manifestations of TB can 
      also vary between HIV-infected patients and uninfected patients, which can 
      increase the risk for delayed diagnosis. Areas covered: Topics covered in this 
      review include the following: the inter-related pathophysiology of HIV and TB; 
      clinical manifestations and diagnosis; drug-drug interactions, particularly the 
      rifamycins with the antiretrovirals; IRIS presentation and treatment, as well as 
      a discussion on overlapping toxicity between the two disease states. Expert 
      commentary: The complexity of managing these two disease states simultaneously 
      requires a multidisciplinary approach to care and dedicated resources. If 
      properly funded, TB/HIV co-infection will continue to decline over the coming 
      years.
FAU - Egelund, Eric F
AU  - Egelund EF
AD  - a Department of Pharmacotherapy and Translational Research , College of Pharmacy.
AD  - b Infectious Disease Pharmacokinetics Laboratory.
FAU - Dupree, Lori
AU  - Dupree L
AD  - a Department of Pharmacotherapy and Translational Research , College of Pharmacy.
FAU - Huesgen, Emily
AU  - Huesgen E
AD  - a Department of Pharmacotherapy and Translational Research , College of Pharmacy.
FAU - Peloquin, Charles A
AU  - Peloquin CA
AD  - a Department of Pharmacotherapy and Translational Research , College of Pharmacy.
AD  - b Infectious Disease Pharmacokinetics Laboratory.
AD  - c Emerging Pathogens Institute , University of Florida , Gainesville , FL , USA.
LA  - eng
PT  - Journal Article
DEP - 20161128
PL  - England
TA  - Expert Rev Clin Pharmacol
JT  - Expert review of clinical pharmacology
JID - 101278296
RN  - 0 (Anti-HIV Agents)
RN  - 0 (Antitubercular Agents)
SB  - IM
MH  - Anti-HIV Agents/administration & dosage/pharmacokinetics/*therapeutic use
MH  - Antitubercular Agents/administration & dosage/pharmacokinetics/*therapeutic use
MH  - Drug Interactions
MH  - HIV Infections/*complications/*drug therapy
MH  - Humans
MH  - Tuberculosis/*complications/*drug therapy
OTO - NOTNLM
OT  - HIV
OT  - Tuberculosis
OT  - drug interactions
OT  - immune reconstitution syndrome
OT  - malabsorption
OT  - rifamycins
OT  - therapeutic drug monitoring
EDAT- 2016/11/10 06:00
MHDA- 2017/03/03 06:00
CRDT- 2016/11/10 06:00
PHST- 2016/11/10 06:00 [pubmed]
PHST- 2017/03/03 06:00 [medline]
PHST- 2016/11/10 06:00 [entrez]
AID - 10.1080/17512433.2017.1259066 [doi]
PST - ppublish
SO  - Expert Rev Clin Pharmacol. 2017 Feb;10(2):213-223. doi: 
      10.1080/17512433.2017.1259066. Epub 2016 Nov 28.